Mycobacterium haemophilum infection after alemtuzumab treatment.
Kamboj
Mini
M
Louie
Eddie
E
Kiehn
Timothy
T
Papanicolaou
Genovefa
G
Glickman
Michael
M
Sepkowitz
Kent
K
D000293:Adolescent; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D021821:Communicable Diseases, Emerging / Q000175:diagnosis* / Q000209:etiology / Q000382:microbiology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D009164:Mycobacterium Infections / Q000175:diagnosis* / Q000209:etiology / Q000382:microbiology; D018393:Mycobacterium haemophilum; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D017192:Skin Diseases, Bacterial / Q000175:diagnosis* / Q000209:etiology / Q000382:microbiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab